Skip to the content
  • Our Company
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Science & Innovation
    • Our Approach
    • Our Pipeline
  • Culture
  • Media
    • Resources
    • News
  • News
  • Contact
  • Our Company
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Science & Innovation
    • Our Approach
    • Our Pipeline
  • Culture
  • Media
    • Resources
    • News
  • News
  • Contact

Immunoreactive peptide maps of SARS-CoV-2

  • Scientific Publication
  • February 12, 2021
  • Scientific Publication
  • February 12, 2021

Mishra, N., Huang, X., Joshi, S. et al. Immunoreactive peptide maps of SARS-CoV-2. Commun Biol 4, 225 (2021). https://doi.org/10.1038/s42003-021-01743-9

Abstract

Serodiagnosis of SARS-CoV-2 infection is impeded by immunological cross-reactivity among the human coronaviruses (HCoVs): SARS-CoV-2, SARS-CoV-1, MERS-CoV, OC43, 229E, HKU1, and NL63. Here we report the identification of humoral immune responses to SARS-CoV-2 peptides that may enable discrimination between exposure to SARS-CoV-2 and other HCoVs. We used a high-density peptide microarray and plasma samples collected at two time points from 50 subjects with SARS-CoV-2 infection confirmed by qPCR, samples collected in 2004–2005 from 11 subjects with IgG antibodies to SARS-CoV-1, 11 subjects with IgG antibodies to other seasonal human coronaviruses (HCoV), and 10 healthy human subjects. Through statistical modeling with linear regression and multidimensional scaling we identified specific peptides that were reassembled to identify 29 linear SARS-CoV-2 epitopes that were immunoreactive with plasma from individuals who had asymptomatic, mild or severe SARS-CoV-2 infections. Larger studies will be required to determine whether these peptides may be useful in serodiagnostics.

PrevPrevious
NextNext
  • Our Team
  • Our Pipeline
  • Partner
  • Resources
  • News
  • Careers
  • Contact
  • Our Team
  • Our Pipeline
  • Partner
  • Resources
  • News
  • Careers
  • Contact
  • CONNECT ON LINKEDIN

Copyright © 2024 Nimble Therapeutics, Inc